488 related articles for article (PubMed ID: 27074786)
1. Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?
Hale CM; Seabury RW; Steele JM; Darko W; Miller CD
J Pharm Pract; 2017 Jun; 30(3):329-335. PubMed ID: 27074786
[TBL] [Abstract][Full Text] [Related]
2. Implementation of vancomycin AUC/MIC dosing vs traditional trough dosing and incidence of acute kidney injury at a rural community hospital.
McClure S; McElroy L; Gugkaeva Z
Am J Health Syst Pharm; 2024 May; 81(11):e283-e288. PubMed ID: 38253056
[TBL] [Abstract][Full Text] [Related]
3. The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review.
Tkachuk S; Collins K; Ensom MHH
Paediatr Drugs; 2018 Apr; 20(2):153-164. PubMed ID: 29344778
[TBL] [Abstract][Full Text] [Related]
4. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies.
Prybylski JP
Pharmacotherapy; 2015 Oct; 35(10):889-98. PubMed ID: 26497475
[TBL] [Abstract][Full Text] [Related]
5. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
6. Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?
Patel K; Crumby AS; Maples HD
Paediatr Drugs; 2015 Apr; 17(2):97-103. PubMed ID: 25644329
[TBL] [Abstract][Full Text] [Related]
7. Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients.
Ploessl C; White C; Manasco K
Pediatr Infect Dis J; 2015 Oct; 34(10):e244-7. PubMed ID: 26121203
[TBL] [Abstract][Full Text] [Related]
8. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
Frymoyer A; Guglielmo BJ; Hersh AL
Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
[TBL] [Abstract][Full Text] [Related]
9. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
[TBL] [Abstract][Full Text] [Related]
10. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
[TBL] [Abstract][Full Text] [Related]
11. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
Kullar R; Davis SL; Levine DP; Rybak MJ
Clin Infect Dis; 2011 Apr; 52(8):975-81. PubMed ID: 21460309
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin: we can't get there from here.
Patel N; Pai MP; Rodvold KA; Lomaestro B; Drusano GL; Lodise TP
Clin Infect Dis; 2011 Apr; 52(8):969-74. PubMed ID: 21460308
[TBL] [Abstract][Full Text] [Related]
13. Examining the Relationship Between Vancomycin Area Under the Concentration Time Curve and Serum Trough Levels in Adults With Presumed or Documented Staphylococcal Infections.
Clark L; Skrupky LP; Servais R; Brummitt CF; Dilworth TJ
Ther Drug Monit; 2019 Aug; 41(4):483-488. PubMed ID: 30817704
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
Lepe JA; Gil-Navarro MV; Santos-Rubio MD; Bautista J; Aznar J
Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Therapeutic Vancomycin Monitoring in Taiwan.
Chen TT; Liu MP; Sun HC
Microbiol Spectr; 2022 Apr; 10(2):e0156221. PubMed ID: 35412391
[TBL] [Abstract][Full Text] [Related]
16. Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.
Meng L; Wong T; Huang S; Mui E; Nguyen V; Espinosa G; Desai J; Holubar M; Deresinski S
Pharmacotherapy; 2019 Apr; 39(4):433-442. PubMed ID: 30739349
[TBL] [Abstract][Full Text] [Related]
17. Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Ghosh N; Chavada R; Maley M; van Hal SJ
Clin Microbiol Infect; 2014 Dec; 20(12):O1098-105. PubMed ID: 24890030
[TBL] [Abstract][Full Text] [Related]
18. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target-Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant
Covvey JR; Erickson O; Fiumara D; Mazzei K; Moszczenski Z; Slipak K; Nemecek BD; Zimmerman DE; Guarascio AJ
Ann Pharmacother; 2020 Jul; 54(7):644-651. PubMed ID: 31888350
[No Abstract] [Full Text] [Related]
20. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]